Prognostic Significance of Serum PD-L1 Level in Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated with Combination Cytotoxic Chemotherapy

References

• Glenn TF. Esophageal cancer. Facts, figures, and screening. Gastroenterol Nurs. 2001;24:271–275. doi:10.1097/00001610-200111000-0000211837211
   PubMedGoogle Scholar
• Wei WQ, Chen ZF, He YT, et al. Long-term follow-up of a community assignment, one-time endoscopic screening study of esophageal cancer in China. J Clin Oncol. 2015;33:1951–1957. doi:10.1200/jco.2014.58.042325940715
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23:1095–1103. doi:10.1093/annonc/mdr43322003242
   PubMed Web of Science ®Google Scholar
• Hirano H, Kato K. Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol. 2019;49:412–420. doi:10.1093/jjco/hyz03430920626
   PubMed Web of Science ®Google Scholar
• Kajiura S, Hosokawa A, Yoshita H, et al. Phase I study of docetaxel plus nedaplatin in patients with metastatic or recurrent esophageal squamous cell carcinoma after cisplatin plus 5-fluorouracil treatment. Am J Clin Oncol. 2016;39:13–17. doi:10.1097/coc.000000000000001824322336
   PubMed Web of Science ®Google Scholar
• Yang PW, Huang PM, Yong LS, et al. Circulating interleukin-6 is associated with prognosis and genetic polymorphisms of MIR608 in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2018;25:2449–2456. doi:10.1245/s10434-018-6532-429948421
   PubMed Web of Science ®Google Scholar
• Bradley CA. Pembrolizumab improves OS across PD-L1 subgroups. Nat Rev Clin Oncol. 2019;16:403. doi:10.1038/s41571-019-0213-5
   Web of Science ®Google Scholar
• Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. doi:10.3389/fphar.2017.0056128878676
   PubMed Web of Science ®Google Scholar
• Bian B, Fanale D, Dusetti N, et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology. 2019;8:e1561120. doi:10.1080/2162402x.2018.156112030906655
   PubMed Web of Science ®Google Scholar
• Shen H, Ji Y, Zhou D, Zhang Y. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. Hematology (Amsterdam, Netherlands). 2019;24:392–398. doi:10.1080/16078454.2019.1590965
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Doi T, Obayashi K, et al. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. Immunol Lett. 2018;196:155–160. doi:10.1016/j.imlet.2018.01.00729366663
   PubMed Web of Science ®Google Scholar
• Chang B, Huang T, Wei H, et al. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 2019;68:353–363. doi:10.1007/s00262-018-2271-430506460
   PubMed Web of Science ®Google Scholar
• Cubillos-Zapata C, Martinez-Garcia MA, Campos-Rodriguez F, et al. Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients. Eur Respir J. 2019;53:1801298. doi:10.1183/13993003.01298-201830487198
   PubMed Web of Science ®Google Scholar
• Kushlinskii NE, Gershtein ES, Morozov AA, et al. Soluble ligand of the immune checkpoint receptor (sPD-L1) in blood serum of patients with renal cell carcinoma. Bull Exp Biol Med. 2019;166:353–357. doi:10.1007/s10517-019-04349-830627905
   PubMed Web of Science ®Google Scholar
• Shigemori T, Toiyama Y, Okugawa Y, et al. Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: direct comparison of the clinical burden between tissue and serum PD-L1 expression. Ann Surg Oncol. 2019;26:876–883. doi:10.1245/s10434-018-07112-x
   PubMed Web of Science ®Google Scholar
• Hsieh CC, Hsu HS, Li AF, Chen YJ. Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. J Thorac Dis. 2018;10:4433–4444. doi:10.21037/jtd.2018.06.16730174892
   PubMed Web of Science ®Google Scholar
• Rong L, Liu Y, Hui Z, et al. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population. Diagn Pathol. 2019;14:6. doi:10.1186/s13000-019-0778-430684971
   PubMed Web of Science ®Google Scholar
• Guo W, Zhang F, Shao F, et al. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. Hum Pathol. 2019;84:291–298. doi:10.1016/j.humpath.2018.09.01430296523
   PubMed Web of Science ®Google Scholar
• Jiang C, Zhu Y, Tang S, et al. High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy. Oncol Lett. 2019;17:1626–1634. doi:10.3892/ol.2018.974730675222
   PubMed Web of Science ®Google Scholar
• Xu F, Xu L, Wang Q, An G, Feng G, Liu F. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med. 2015;8:14595–14603.26628942
   PubMed Web of Science ®Google Scholar
• Kim JW, Nam KH, Ahn SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 2016;19:42–52. doi:10.1007/s10120-014-0440-525424150
   PubMed Web of Science ®Google Scholar
• Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med. 2013;5:200ra116. doi:10.1126/scitranslmed.3006504
   PubMed Web of Science ®Google Scholar
• Loosen SH, Heise D, Dejong CH, Roy S, Tacke F. Circulating levels of osteopontin predict patients’ outcome after resection of colorectal liver metastases. J Clin Med. 2018;7:390. doi:10.3390/jcm7110390
   PubMed Web of Science ®Google Scholar
• Cho Y, Kim JW, Yoon HI, Lee CG, Keum KC, Lee IJ. The prognostic significance of neutrophil-to-lymphocyte ratio in head and neck cancer patients treated with radiotherapy. J Clin Med. 2018;7:512. doi:10.3390/jcm7120512
   PubMed Web of Science ®Google Scholar
• Ha H, Nam AR, Bang JH, et al. Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. Oncotarget. 2016;7:76604–76612. doi:10.18632/oncotarget.1281027780932
   PubMedGoogle Scholar
• Costantini A, Julie C, Dumenil C, et al. Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. Oncoimmunology. 2018;7:e1452581. doi:10.1080/2162402x.2018.145258130221046
   PubMed Web of Science ®Google Scholar
• Frigola X, Inman BA, Lohse CM, et al. Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res. 2011;17:1915–1923. doi:10.1158/1078-0432.ccr-10-025021355078
   PubMed Web of Science ®Google Scholar
• Rossille D, Gressier M, Damotte D, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014;28:2367–2375. doi:10.1038/leu.2014.13724732592
   PubMed Web of Science ®Google Scholar
• Zhao J, Zhang P, Wang J, et al. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Medicine. 2017;96:e6102. doi:10.1097/md.000000000000610228207525
   PubMed Web of Science ®Google Scholar